Awards for “GLAXOSMITHKLINE, LLC”
25 awards on this page · sorted by amount · page 1
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| W58P0522C0002 | GLAXOSMITHKLINE, LLC | Department of Defense | $1.6B | 2021-11-15 | 2023-09-30 | 325412 | :COVID-19: SOTROVIMAB MONOCLONAL ANDTIBODIES |
| HHSD200201793272C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $682.17M | 2017-04-01 | 2018-03-31 | 423450 | IGF::OT::IGF VACINES FOR CHILDREN |
| HHSD200201458151C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $602.05M | 2014-04-01 | 2015-03-31 | 325412 | VACCINE FOR CHILDREN (VFC) 2014 |
| HHSD200201250132C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $554.78M | 2012-04-01 | 2013-03-31 | 325412 | VACCCINE FOR CHILDREN 2012 |
| HHSD200201354510C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $526.07M | 2013-04-01 | 2014-03-31 | 325412 | VACCINE FOR CHILDREN 2013 |
| W15QKN20C0048 | GLAXOSMITHKLINE, LLC | Department of Defense | $335.59M | 2020-07-30 | 2022-12-30 | 325412 | GLAXOSMITHKLINE ADJUVANT AS03 |
| W58P0521C0008 | GLAXOSMITHKLINE, LLC | Department of Defense | $279.86M | 2021-09-24 | 2022-05-19 | 325412 | :COVID-19: MONOCLONAL ANTIBODY (MAB) THERAPEUTIC SOTROVIMAB |
| HHSD200201792735C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $90.86M | 2016-12-23 | 2018-02-28 | 325411 | IGF:OT:IGF 2017 ADULT FLU |
| HHSD2002014602890003 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $66.37M | 2015-03-19 | 2015-09-30 | 325414 | TASK ORDER 0003 |
| HHSD200201688484C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $55.97M | 2015-12-18 | 2017-02-28 | 325412 | IGF::OT::IGF 2016 PED FLU |
| HHSD200201354020C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $51.01M | 2013-02-22 | 2014-02-21 | 325412 | PEDIATRIC FLU VACCINE |
| HHSD200201561388C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $50.72M | 2015-02-06 | 2016-02-28 | 325412 | 2015-2016 PEDIATRIC FLU VACCINES |
| HHSD2002014602890006 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $50M | 2017-09-20 | 2018-12-31 | 325414 | MODIFICATION 00001: CLARIFICATION OF SHELF-LIFE DATING |
| HHSD200201457658C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $49.6M | 2014-02-05 | 2015-02-28 | 325412 | PEDIATRIC FLU VACCINES 2014-2015 |
| 75D30118F00007 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $40.55M | 2018-09-19 | 2019-09-18 | 325414 | FY18 PRODUCT PROCUREMENT |
| HHSD2002014602890002 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $33M | 2014-09-23 | 2015-09-22 | 325414 | TASK ORDER 0002 |
| 75A50122F61004 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $22.88M | 2022-09-14 | 2025-06-30 | 541714 | THE PURPOSE OF THIS TASK ORDER IS TO PROCURE INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8) VIRUS VACCINE CANDIDATE AND CLINICAL TRIAL FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES UNDER IDIQ CONTRACT # 75A50122D00002 BASE PERIOD. |
| HHSD200201251346C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $20.58M | 2012-07-06 | 2013-06-30 | 325414 | 2012 ADULT VACCINES |
| HHSD200201562835C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $19.53M | 2015-07-01 | 2016-06-30 | 325411 | VACCINES FOR ADULTS |
| SPE2DP22F3107 | GLAXOSMITHKLINE, LLC | Department of Defense | $18.85M | 2022-08-31 | 2022-08-31 | 325412 | 8508921650!INFLUENZA VIRUS VAC |
| 75A50325C00019 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $18.2M | 2025-09-30 | 2027-09-29 | 325412 | RELENZA (ZANAMIVIR) ROTADISK, 5MG |
| 75A50124F61014 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $18.19M | 2024-05-10 | 2027-02-21 | 541714 | THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND EMERGING DISEASES PREPAREDNESS AND RESPONSE UNDER CONTRACT 75A50122D00002. |
| 75A50119F33009 | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $18.16M | 2019-08-28 | 2024-04-29 | 325414 | AS03B-H7N9 VACCINE CLINICAL STUDY |
| SPE2DP21F2380 | GLAXOSMITHKLINE, LLC | Department of Defense | $17.47M | 2021-02-26 | 2021-08-20 | 339112 | 8508019609!INFLUENZA VIRUS VAC |
| HHSD200201690099C | GLAXOSMITHKLINE, LLC | Department of Health and Human Services | $16.37M | 2016-07-01 | 2017-06-30 | 325411 | IGF::OT::IGF 2016 VFA - GSK |